Adult and special risk groups



| Eligible groups | | Disease | Vaccine brand | Route of administration | Notes | | |
|-------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Pregnancy All pregnant women – every pregnancy | | Influenza | See influenza on Additional Notes for Vaccination | 0.5ml IMI | Any stage of pregnancy | | |
| | | Diphtheria, tetanus, pertussis | Boostrix or Adacel | 0.5ml IMI | From 20 weeks of pregnancy | | |
| All adults | From 16 years of age | COVID-19 | See COVID-19 Vaccine Administration Protocols (CVAP) | IMI | 2 doses if not already immunised Vaccinators must complete mandatory COVID-19 training prior to administering COVID-19 vaccine | | |
| | Born after 1966 Who have not received two MMR vaccines or who are not immune | Measles, mumps, rubella (MMR) | M-M-R II or Priorix | 0.5ml SC or IMI | Give 2 doses, 1 month between doses | | |
| | From 65 years of age | Influenza | Fluad Quad | 0.5ml IMI | Annually | | |
| | From 70 years of age | Herpes Zoster (shingles) | Zostavax | 0.65ml SC | Single dose at 70 years of age. All people aged 71 to 79 years can receive the Zostavax vaccine as part of the catch up program - give one dose only | | |
| | Non-Aboriginal adults from 70 years of age | Pneumococcal | Prevenar 13 | 0.5ml IMI | Refer to NT Pneumococcal vaccination schedule | | |
| | With risk conditions | Pneumococcal | Refer to NT Pneumococcal vaccination schedule for dosing and risk conditions | | | | |
| | Refer to disease-specific risk conditions lists for recommendations and eligibility in Australian Immunisation Handbook. | | | | | | |
| | | Influenza | Refer to NT Vaccination Schedule Additional notes influenza for risk conditions | | | | |
| | Other vaccines may also be required for specific conditions refer to Australian Immunisation Handbook. | | | | | | |
| Aboriginal adults | All ages | Influenza | See influenza on Additional Notes for age eligibility | 0.5ml IMI | Annually | | |
| | 20 to 50 years If not previously vaccinated or who do not have immunity through natural infection. | Hepatitis B | Engerix – B adult or H-B-Vax II | 1ml IMI | 3 doses (0, 1 and 6 months) | | |
| | 50 years and over With no risk conditions | Pneumococcal | Prevenar 13 | 0.5ml IMI | Consider Pneumovax 23 requirement - See NT Pneumococcal vaccination schedule | | |
| Refugees and other humanitarian entrants Aged 20 years and over For under 20 years refer to NT Childhood Vaccination Schedule | | Diphtheria, tetanus, pertussis | Boostrix or Adacel | Boostrix or Adacel 0.5ml IMI For recommendations reformunisation Handbook | | | |
| | | Poliomyelitis | IPOL | 0.5ml SC | immunisationhandbook.health.gov.au/catch- | | |
| | | Measles, mumps, rubella | M-M-R II or Priorix | up-vaccination | | | |
| | | Hepatitis B | Engerix – B adult | Engerix – B adult 1ml IMI | | | |
| | | Varicella | Varilrix or Varivax 0.5ml SC | | | | |
| | | COVID-19 | See COVID-19 Vaccine Administration Protocols IMI 2 doses if not already immunised Vaccinators must complete mandatory COVID-19 training prior to administering COVID-19 vaccine | | | | |



Children (up to 19 years)



| Age | Disease | Vaccine brand | Dose no. | Reconstitute | Route of administration | Notes |
|---------------------------------|-------------------------------------|-----------------------------------------------------|----------|--------------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Birth | Hepatitis B | H-B-Vax II or Engerix- B paediatric | 1 | * | IMI | ALL CHILDREN, Give within 7 days of birth |
| 6 weeks | DTPa-HepB-IPV-Hib | Infanrix hexa | 1 | ✓ | IMI | ALL CHILDREN |
| | Pneumococcal | Prevenar 13 | 1 | × | IMI | ALL CHILDREN |
| | Rotavirus | Rotarix | 1 | * | ORAL | ALL CHILDREN, Dose 1 must be given before 15 weeks of age |
| | Meningococcal B | Bexsero | 1 | × | IMI | Aboriginal children. Prophylactic paracetamol |
| 4 months | DTPa-HepB-IPV-Hib | Infanrix hexa | 2 | ✓ | IMI | ALL CHILDREN |
| | Pneumococcal | Prevenar 13 | 2 | * | IMI | ALL CHILDREN |
| | Rotavirus | Rotarix | 2 | * | ORAL | ALL CHILDREN, Dose 2 must be given before 25 weeks of age |
| | Meningococcal B* | Bexsero | 2 | * | IMI | Aboriginal children. Prophylactic paracetamol |
| 6 months | DTPa-HepB-IPV-Hib | Infanrix hexa | 3 | ✓ | IMI | ALL CHILDREN |
| | Pneumococcal | Prevenar 13 | 3 | * | IMI | Aboriginal children |
| | | | | | | Medically at risk – please refer to the Australian Immunisation Handbook for details |
| 6 months to under 5 years | Influenza | See Additional Notes - Influenza | Annually | * | IMI | ALL CHILDREN. If receiving vaccine for the first time in their life: give 2 doses, 1 month between doses. 1 dose annually thereafter |
| 12 | Measles-mumps-rubella | Priorix or MMR II | 1 | ✓ | SC OR IMI | ALL CHILDREN |
| months | Meningococcal ACWY | Nimenrix | 1 | ✓ | IMI | ALL CHILDREN |
| | Pneumococcal | Prevenar 13 | 3 or 4 | * | IMI | ALL CHILDREN |
| | Meningococcal B* | Bexsero | 3 | × | IMI | Aboriginal children. Prophylactic paracetamol |
| | Hepatitis B | H-B-Vax II or Engerix-B paediatric | 4 | * | IMI | Premature infants under 32 weeks or under 2000g at birth |
| 18 months | Measles-mumps-rubella- varicella | Priorix-tetra or ProQuad | 2 | √ | SC or IMI | ALL CHILDREN |
| | Haemophilus influenzae type b | Act-HIB | 4 | ✓ | IMI | ALL CHILDREN |
| | DTPa | Infanrix or Tripacel | 4 | * | IMI | ALL CHILDREN |
| | Hepatitis A | VAQTA | 1 | * | IMI | Aboriginal children |
| 4 years | DTPa-IPV | Infanrix IPV or Quadracel | 5 | * | IMI | ALL CHILDREN |
| | Hepatitis A | VAQTA | 2 | * | IMI | Aboriginal children who have not had 2 doses previously |
| | Pneumococcal | Pneumovax 23 | 1 | * | IMI | Aboriginal children Medically at risk – please refer to the Australian Immunisation Handbook for details |
| 5-19 years | Influenza | See Additional Notes - Influenza | Annually | × | IMI | Aboriginal children. If receiving vaccine for the first time in their life and aged under 9 years: give 2 doses, 1 month between doses. 1 dose annually thereafter. |
| 12 years | Human Papillomavirus | Gardasil 9 | 1 and 2 | * | IMI | ALL CHILDREN minimum 6 month interval between doses 1 and 2 Medically at risk - 3 dose course: 0, 2 and 6 months (see Australian Immunisation |
| | Adult /adalassant dTna | Boostrix or Adacel | 1 | | IMI | Handbook for specific risk conditions) ALL CHILDREN |
| 14.40 | Adult/adolescent dTpa | | 1 | * | | |
| 14-19 years | Meningococcal ACWY Pneumococcal | Nimenrix Pneumovax 23 | 2 | × | IMI IMI | ALL CHILDREN Aboriginal children |
| | | | | | | Medically at risk – please refer to the Australian Immunisation Handbook for details |
| COVID-19 | | See COVID-19 Vaccine Administration Protocols | 1 and 2 | ✓ | IMI | Vaccinators must complete mandatory COVID-19 training prior to administering COVID-19 vaccine |

 $^{^{*}}$ catch-up schedule available, see additional notes.

